En direct

CRCM PhD Day 2021 will take place on May 28 2021 - Les mitochondries nouvelles cibles thérapeutiques potentielles dans le cancer du pancréas - La cycline A2, qui maintient l'homéostasie du côlon, est un facteur de pronostic dans le cancer colorectal -

Apr 2016 European journal of endocrinology

Quality of life, clinical outcomes and safety of early prophylactic levothyroxine administration in patients with Graves’ hyperthyroidism undergoing radioiodine therapy: a randomized controlled study.

Auteurs

Taïeb D, Bournaud C, Eberle MC, Catargi B, Schvartz C, Cavarec MB, Faugeron I, Toubert ME, Benisvy D, Archange C, Mundler O, Caron P, Abdullah AE, Baumstarck K

Résumé

While radioiodine therapy is commonly used for treating Graves’ disease, a prolonged and clinical hypothyroidism may result in disabling symptoms leading to deterioration of quality of life (QoL) of patients. Introducing levothyroxine (LT4) treatment in the early post-therapeutic period may be an interesting approach to limit this phenomenon.

Lire l‘article